Concepts (261)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 23 | 2018 | 446 | 4.830 |
Why?
|
| Population Surveillance | 11 | 2021 | 252 | 3.500 |
Why?
|
| Hepatitis C | 5 | 2020 | 65 | 2.520 |
Why?
|
| Disabled Persons | 5 | 2023 | 35 | 2.490 |
Why?
|
| Registries | 20 | 2021 | 460 | 2.310 |
Why?
|
| United States | 46 | 2022 | 3866 | 1.960 |
Why?
|
| Humans | 65 | 2023 | 17314 | 1.400 |
Why?
|
| Incidence | 23 | 2021 | 1266 | 1.280 |
Why?
|
| Adult | 36 | 2022 | 7500 | 1.180 |
Why?
|
| Survivors | 6 | 2016 | 157 | 1.170 |
Why?
|
| Mammography | 8 | 2015 | 168 | 1.130 |
Why?
|
| Breast Neoplasms | 14 | 2018 | 969 | 1.090 |
Why?
|
| Young Adult | 17 | 2021 | 2465 | 1.020 |
Why?
|
| Female | 47 | 2021 | 12396 | 1.000 |
Why?
|
| Adolescent | 18 | 2023 | 3538 | 0.970 |
Why?
|
| Aged | 28 | 2022 | 6084 | 0.970 |
Why?
|
| Developmental Disabilities | 4 | 2023 | 52 | 0.960 |
Why?
|
| Anthracyclines | 2 | 2016 | 14 | 0.960 |
Why?
|
| Middle Aged | 33 | 2021 | 7836 | 0.930 |
Why?
|
| Early Detection of Cancer | 6 | 2015 | 529 | 0.930 |
Why?
|
| Male | 34 | 2021 | 9804 | 0.870 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 42 | 0.810 |
Why?
|
| Poliovirus | 1 | 2022 | 1 | 0.790 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2022 | 3 | 0.790 |
Why?
|
| Poliomyelitis | 1 | 2022 | 2 | 0.790 |
Why?
|
| Mass Screening | 8 | 2020 | 672 | 0.770 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 202 | 0.770 |
Why?
|
| Hepatitis C, Chronic | 2 | 2020 | 74 | 0.730 |
Why?
|
| Gallbladder Neoplasms | 1 | 2021 | 3 | 0.720 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 5 | 0.720 |
Why?
|
| Disease Notification | 1 | 2020 | 7 | 0.660 |
Why?
|
| Child | 13 | 2023 | 2403 | 0.660 |
Why?
|
| Vaccination | 2 | 2023 | 688 | 0.640 |
Why?
|
| Hepacivirus | 1 | 2019 | 52 | 0.620 |
Why?
|
| SEER Program | 10 | 2017 | 92 | 0.590 |
Why?
|
| Sex Distribution | 7 | 2017 | 180 | 0.570 |
Why?
|
| Public Health Administration | 1 | 2017 | 6 | 0.540 |
Why?
|
| Age Distribution | 9 | 2017 | 239 | 0.540 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2016 | 7 | 0.510 |
Why?
|
| Cardiotoxins | 1 | 2014 | 1 | 0.460 |
Why?
|
| Echocardiography, Stress | 1 | 2014 | 2 | 0.460 |
Why?
|
| Prevalence | 5 | 2019 | 840 | 0.450 |
Why?
|
| Heart Rate | 1 | 2014 | 38 | 0.450 |
Why?
|
| Breast | 1 | 2015 | 84 | 0.440 |
Why?
|
| Heart Diseases | 1 | 2014 | 71 | 0.440 |
Why?
|
| Exercise | 2 | 2018 | 515 | 0.420 |
Why?
|
| Child, Preschool | 8 | 2023 | 1380 | 0.410 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 1925 | 0.400 |
Why?
|
| Quality of Life | 1 | 2016 | 499 | 0.390 |
Why?
|
| Medicare | 4 | 2022 | 192 | 0.380 |
Why?
|
| Ovarian Neoplasms | 2 | 2014 | 52 | 0.360 |
Why?
|
| Infant, Newborn | 5 | 2021 | 805 | 0.360 |
Why?
|
| Neoplasm Invasiveness | 5 | 2017 | 79 | 0.340 |
Why?
|
| Infant | 5 | 2021 | 1161 | 0.330 |
Why?
|
| Poverty | 4 | 2015 | 168 | 0.330 |
Why?
|
| Survival Rate | 5 | 2017 | 252 | 0.330 |
Why?
|
| Autism Spectrum Disorder | 2 | 2023 | 159 | 0.330 |
Why?
|
| Age Factors | 6 | 2015 | 878 | 0.310 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2008 | 6 | 0.300 |
Why?
|
| Mouth Neoplasms | 1 | 2008 | 9 | 0.300 |
Why?
|
| Nutrition Surveys | 2 | 2018 | 56 | 0.300 |
Why?
|
| Disability Evaluation | 2 | 2006 | 45 | 0.260 |
Why?
|
| Papillomavirus Infections | 1 | 2008 | 142 | 0.260 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2017 | 16 | 0.260 |
Why?
|
| Time Factors | 7 | 2018 | 1039 | 0.260 |
Why?
|
| Health Services Accessibility | 4 | 2020 | 271 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 310 | 0.220 |
Why?
|
| Risk Factors | 3 | 2021 | 3258 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2022 | 381 | 0.200 |
Why?
|
| Immunization | 1 | 2023 | 69 | 0.200 |
Why?
|
| New York | 1 | 2022 | 17 | 0.200 |
Why?
|
| Vaccination Coverage | 1 | 2023 | 52 | 0.190 |
Why?
|
| Colorectal Neoplasms | 5 | 2018 | 622 | 0.190 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 81 | 0.190 |
Why?
|
| Neoplasm Staging | 4 | 2017 | 338 | 0.190 |
Why?
|
| Health Care Surveys | 2 | 2021 | 211 | 0.190 |
Why?
|
| Intention | 1 | 2021 | 30 | 0.180 |
Why?
|
| Zika Virus | 1 | 2021 | 1 | 0.180 |
Why?
|
| Phthiraptera | 1 | 2021 | 1 | 0.180 |
Why?
|
| Mycoplasma | 1 | 2021 | 1 | 0.180 |
Why?
|
| Dysentery, Bacillary | 1 | 2021 | 2 | 0.180 |
Why?
|
| Zika Virus Infection | 1 | 2021 | 3 | 0.180 |
Why?
|
| Gonorrhea | 1 | 2021 | 19 | 0.180 |
Why?
|
| Chlamydia Infections | 1 | 2021 | 23 | 0.180 |
Why?
|
| Syphilis | 1 | 2021 | 17 | 0.170 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2021 | 54 | 0.170 |
Why?
|
| Parents | 1 | 2023 | 297 | 0.170 |
Why?
|
| Death Certificates | 2 | 2017 | 17 | 0.160 |
Why?
|
| Sex Factors | 3 | 2017 | 603 | 0.160 |
Why?
|
| American Cancer Society | 2 | 2017 | 12 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 1280 | 0.160 |
Why?
|
| Acute Disease | 1 | 2020 | 144 | 0.160 |
Why?
|
| Comorbidity | 1 | 2021 | 560 | 0.160 |
Why?
|
| Data Collection | 2 | 2017 | 238 | 0.150 |
Why?
|
| Residence Characteristics | 3 | 2015 | 253 | 0.150 |
Why?
|
| Diabetes Mellitus | 1 | 2003 | 452 | 0.150 |
Why?
|
| Health Status Disparities | 2 | 2017 | 149 | 0.150 |
Why?
|
| Cultural Diversity | 1 | 2018 | 17 | 0.140 |
Why?
|
| Tobacco Use | 1 | 2018 | 14 | 0.140 |
Why?
|
| Financing, Government | 2 | 2008 | 26 | 0.140 |
Why?
|
| Cause of Death | 2 | 2016 | 176 | 0.140 |
Why?
|
| Models, Statistical | 1 | 2018 | 170 | 0.140 |
Why?
|
| Influenza Vaccines | 1 | 2020 | 292 | 0.140 |
Why?
|
| Influenza, Human | 1 | 2020 | 282 | 0.130 |
Why?
|
| Patient Selection | 2 | 2015 | 176 | 0.130 |
Why?
|
| Vital Statistics | 1 | 2017 | 1 | 0.130 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2017 | 34 | 0.130 |
Why?
|
| Hospitalization | 1 | 2022 | 804 | 0.130 |
Why?
|
| Cancer Survivors | 1 | 2018 | 101 | 0.130 |
Why?
|
| Cardiotoxicity | 1 | 2016 | 1 | 0.130 |
Why?
|
| Women's Health Services | 2 | 2006 | 15 | 0.130 |
Why?
|
| Health Policy | 1 | 2017 | 109 | 0.130 |
Why?
|
| Diet | 2 | 2018 | 355 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 120 | 0.120 |
Why?
|
| Linear Models | 1 | 2016 | 206 | 0.120 |
Why?
|
| Preventive Health Services | 2 | 2008 | 147 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 28 | 0.120 |
Why?
|
| Patient Care Planning | 1 | 2015 | 45 | 0.120 |
Why?
|
| Information Dissemination | 1 | 2015 | 50 | 0.120 |
Why?
|
| Symptom Assessment | 1 | 2015 | 6 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2015 | 76 | 0.120 |
Why?
|
| Public Health | 1 | 2015 | 83 | 0.120 |
Why?
|
| HIV Infections | 1 | 2021 | 712 | 0.110 |
Why?
|
| Uterine Neoplasms | 1 | 2014 | 13 | 0.110 |
Why?
|
| Indians, North American | 1 | 2014 | 48 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 145 | 0.110 |
Why?
|
| Logistic Models | 3 | 2013 | 879 | 0.100 |
Why?
|
| Medicine | 2 | 2009 | 18 | 0.100 |
Why?
|
| Socioeconomic Factors | 4 | 2022 | 605 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 102 | 0.090 |
Why?
|
| Medical Oncology | 2 | 2009 | 32 | 0.090 |
Why?
|
| Endocrine System Diseases | 1 | 2011 | 2 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 191 | 0.090 |
Why?
|
| Obesity | 1 | 2018 | 814 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2013 | 134 | 0.090 |
Why?
|
| Counseling | 1 | 2013 | 174 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 701 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2015 | 704 | 0.080 |
Why?
|
| Pandemics | 2 | 2023 | 287 | 0.080 |
Why?
|
| Carcinoma, Lobular | 1 | 2009 | 10 | 0.080 |
Why?
|
| Carcinoma in Situ | 1 | 2009 | 17 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2008 | 19 | 0.080 |
Why?
|
| Tongue Neoplasms | 1 | 2008 | 1 | 0.080 |
Why?
|
| Tonsillar Neoplasms | 1 | 2008 | 2 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2009 | 52 | 0.080 |
Why?
|
| Continuity of Patient Care | 1 | 2009 | 103 | 0.070 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2008 | 11 | 0.070 |
Why?
|
| Animals | 6 | 2021 | 280 | 0.070 |
Why?
|
| Women's Health | 2 | 2006 | 197 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 27 | 0.070 |
Why?
|
| Program Development | 1 | 2006 | 63 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2006 | 62 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2006 | 131 | 0.050 |
Why?
|
| Polychlorinated Biphenyls | 1 | 1984 | 12 | 0.050 |
Why?
|
| Emergencies | 1 | 2023 | 6 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 1984 | 65 | 0.050 |
Why?
|
| Hydrocodone | 1 | 1982 | 1 | 0.050 |
Why?
|
| Codeine | 1 | 1982 | 2 | 0.050 |
Why?
|
| Analgesics | 1 | 1982 | 27 | 0.050 |
Why?
|
| Narcotic Antagonists | 1 | 1982 | 18 | 0.050 |
Why?
|
| Education, Special | 1 | 2022 | 2 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2003 | 270 | 0.050 |
Why?
|
| Genitalia | 1 | 2021 | 2 | 0.040 |
Why?
|
| Length of Stay | 1 | 2022 | 171 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 535 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2023 | 1098 | 0.040 |
Why?
|
| Seasons | 1 | 2020 | 113 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2022 | 161 | 0.040 |
Why?
|
| Insurance Coverage | 2 | 2012 | 104 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 390 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 70 | 0.040 |
Why?
|
| Tobacco Products | 1 | 2018 | 14 | 0.040 |
Why?
|
| Los Angeles | 1 | 2018 | 139 | 0.030 |
Why?
|
| Minority Groups | 1 | 2018 | 104 | 0.030 |
Why?
|
| Polymers | 4 | 1981 | 5 | 0.030 |
Why?
|
| Life Style | 1 | 2018 | 316 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 2 | 2008 | 124 | 0.030 |
Why?
|
| Appalachian Region | 1 | 2016 | 1 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 25 | 0.030 |
Why?
|
| Food Coloring Agents | 3 | 1981 | 4 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 189 | 0.030 |
Why?
|
| Data Accuracy | 1 | 2016 | 24 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2015 | 5 | 0.030 |
Why?
|
| Breast Neoplasms, Male | 1 | 2015 | 10 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 211 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2015 | 50 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2015 | 47 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 53 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 82 | 0.030 |
Why?
|
| Alaska | 1 | 2014 | 16 | 0.030 |
Why?
|
| Nebraska | 1 | 2014 | 1 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2014 | 43 | 0.030 |
Why?
|
| Dogs | 2 | 1984 | 19 | 0.030 |
Why?
|
| Prognosis | 1 | 2015 | 603 | 0.030 |
Why?
|
| Intestinal Absorption | 4 | 1981 | 5 | 0.030 |
Why?
|
| Kidney | 2 | 1984 | 52 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 357 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 87 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2011 | 2415 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2012 | 65 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 231 | 0.020 |
Why?
|
| Georgia | 1 | 2012 | 14 | 0.020 |
Why?
|
| Marital Status | 1 | 2012 | 20 | 0.020 |
Why?
|
| Physical Examination | 1 | 2011 | 19 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2012 | 45 | 0.020 |
Why?
|
| Liver | 2 | 1982 | 34 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 75 | 0.020 |
Why?
|
| Rural Population | 1 | 2012 | 55 | 0.020 |
Why?
|
| Urban Population | 1 | 2012 | 109 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2013 | 257 | 0.020 |
Why?
|
| Antioxidants | 3 | 1980 | 40 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 640 | 0.020 |
Why?
|
| Professional Practice | 1 | 2009 | 5 | 0.020 |
Why?
|
| Physicians, Family | 1 | 2009 | 36 | 0.020 |
Why?
|
| Rats | 4 | 1982 | 35 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2012 | 235 | 0.020 |
Why?
|
| Specialization | 1 | 2008 | 21 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1151 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 1282 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 1076 | 0.020 |
Why?
|
| Medically Underserved Area | 1 | 2008 | 11 | 0.020 |
Why?
|
| Bile | 3 | 1982 | 5 | 0.020 |
Why?
|
| Community Health Services | 1 | 2008 | 79 | 0.020 |
Why?
|
| Health Surveys | 1 | 2008 | 245 | 0.020 |
Why?
|
| Genital Neoplasms, Female | 1 | 2006 | 2 | 0.020 |
Why?
|
| Self Care | 1 | 2008 | 144 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2008 | 147 | 0.020 |
Why?
|
| Anxiety | 1 | 2008 | 154 | 0.020 |
Why?
|
| Papanicolaou Test | 1 | 2006 | 37 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2006 | 47 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2008 | 163 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 496 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2008 | 277 | 0.020 |
Why?
|
| Health Promotion | 1 | 2008 | 279 | 0.010 |
Why?
|
| Health Maintenance Organizations | 1 | 2006 | 407 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 1984 | 3 | 0.010 |
Why?
|
| Omentum | 1 | 1984 | 2 | 0.010 |
Why?
|
| Testis | 1 | 1984 | 3 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 1984 | 2 | 0.010 |
Why?
|
| Myocardium | 1 | 1984 | 6 | 0.010 |
Why?
|
| Adrenal Glands | 1 | 1982 | 1 | 0.010 |
Why?
|
| Spleen | 1 | 1982 | 4 | 0.010 |
Why?
|
| Species Specificity | 1 | 1982 | 5 | 0.010 |
Why?
|
| Food Additives | 2 | 1979 | 3 | 0.010 |
Why?
|
| Lung | 1 | 1982 | 60 | 0.010 |
Why?
|
| Butylated Hydroxytoluene | 1 | 1980 | 1 | 0.010 |
Why?
|
| Oxidoreductases | 1 | 1980 | 1 | 0.010 |
Why?
|
| Intestines | 1 | 1980 | 5 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1980 | 7 | 0.010 |
Why?
|
| Feces | 4 | 1981 | 85 | 0.010 |
Why?
|
| Azo Compounds | 1 | 1977 | 1 | 0.010 |
Why?
|
| Naphthalenesulfonates | 1 | 1977 | 1 | 0.010 |
Why?
|
| Tartrazine | 1 | 1977 | 1 | 0.010 |
Why?
|
| Organ Size | 1 | 1980 | 16 | 0.000 |
Why?
|
| Vinyl Compounds | 1 | 1978 | 1 | 0.000 |
Why?
|
| Mice, Inbred ICR | 1 | 1978 | 3 | 0.000 |
Why?
|
| Tissue Distribution | 1 | 1978 | 8 | 0.000 |
Why?
|
| Mice | 1 | 1978 | 80 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1977 | 1 | 0.000 |
Why?
|
| Colorimetry | 1 | 1977 | 1 | 0.000 |
Why?
|
| Biotransformation | 1 | 1977 | 3 | 0.000 |
Why?
|
Concepts
(261)
Derived automatically from this person's publications.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->